| Literature DB >> 28655554 |
Safietou Sankhe1, Sevasti Manousakidi1, Fabrice Antigny1, Jennifer Arthur Ataam1, Sana Bentebbal2, Yann Ruchon1, Florence Lecerf1, Jessica Sabourin3, Laura Price4, Elie Fadel1, Peter Dorfmüller1, Saadia Eddahibi2, Marc Humbert5, Frédéric Perros1, Véronique Capuano6.
Abstract
Idiopathic pulmonary arterial hypertension (iPAH) is characterized by obstructive hyperproliferation and apoptosis resistance of distal pulmonary artery smooth muscle cells (PASMCs). T-type Ca2+ channel blockers have been shown to reduce experimental pulmonary hypertension, although the impact of T-type channel inhibition remains unexplored in PASMCs from iPAH patients. Here we show that T-type channels Cav3.1 and Cav3.2 are present in the lung and PASMCs from iPAH patients and control subjects. The blockade of T-type channels by the specific blocker, TTA-A2, prevents cell cycle progression and PASMCs growth. In iPAH cells, T-type channel signaling fails to activate phosphatase PP2A, leading to an increase in ERK1/2, P38 activation. Moreover, T-type channel signaling is redirected towards the activation of the kinase Akt1, leading to increased expression of the anti-apoptotic protein survivin, and a decrease in the pro-apoptotic mediator FoxO3A. Finally, in iPAH cells, Akt1 is no longer able to regulate caspase 9 activation, whereas T-type channel overexpression reverses PP2A defect in iPAH cells but reinforces the deleterious effects of Akt1 activation. Altogether, these data highlight T-type channel signaling as a strong trigger of the pathological phenotype of PASMCs from iPAH patients (hyper-proliferation/cells survival and apoptosis resistance), suggesting that both T-type channels and PP2A may be promising therapeutic targets for pulmonary hypertension.Entities:
Keywords: Caspase; Cell cycle; FoxO3A; Lung; MAPkinase; Survivin
Mesh:
Substances:
Year: 2017 PMID: 28655554 DOI: 10.1016/j.bbamcr.2017.06.018
Source DB: PubMed Journal: Biochim Biophys Acta Mol Cell Res ISSN: 0167-4889 Impact factor: 4.739